Beta Bionics Inc (BBNX)

Currency in USD
16.79
+0.03(+0.18%)
Closed·
Pre Market
16.790.00(0.00%)
·
BBNX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
16.5717.50
52 wk Range
8.8924.50
Key Statistics
Prev. Close
16.79
Open
17.05
Day's Range
16.57-17.5
52 wk Range
8.89-24.5
Volume
1.13M
Average Volume (3m)
552.08K
1-Year Change
-
Book Value / Share
7.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BBNX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.67
Upside
+40.96%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Beta Bionics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Beta Bionics Inc Company Profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Beta Bionics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.39 beat forecasts; revenue up 54% YoY to $23.2M; stock rose 4.79% after-hours
  • Full-year 2025 net sales guidance raised to $88-$93M; Q3 revenue expected to slightly exceed Q2
  • New patient starts grew 57% YoY; expansion into new sales territories and pharmacy channels drove growth
  • CEO highlighted Islet pump's automation and supported CMS's intent to modernize diabetes payment models
  • Risks include regulatory changes, market competition, supply chain issues, and product development delays
Last Updated: 29/07/2025, 22:50
Read Full Transcript

Compare BBNX to Peers and Sector

Metrics to compare
BBNX
Peers
Sector
Relationship
P/E Ratio
−10.3x−3.8x−0.5x
PEG Ratio
-−0.250.00
Price/Book
2.3x2.8x2.6x
Price / LTM Sales
10.5x3.2x3.2x
Upside (Analyst Target)
48.9%33.2%43.8%
Fair Value Upside
Unlock11.7%8.1%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 23.67
(+40.96% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.39 / -0.42
Revenue / Forecast
23.20M / --
EPS Revisions
Last 90 days

BBNX Income Statement

People Also Watch

3.740
PRME
-4.59%
114.13
CRWV
+10.92%
37.54
AS
-3.37%
18.690
LQDA
-2.20%
7.810
YALA
+2.36%

FAQ

What Stock Exchange Does Beta Bionics Trade On?

Beta Bionics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Beta Bionics?

The stock symbol for Beta Bionics is "BBNX."

What Is the Beta Bionics Market Cap?

As of today, Beta Bionics market cap is 729.86M.

What Is Beta Bionics's Earnings Per Share (TTM)?

The Beta Bionics EPS (TTM) is -5.66.

From a Technical Analysis Perspective, Is BBNX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Beta Bionics Stock Split?

Beta Bionics has split 0 times.

How Many Employees Does Beta Bionics Have?

Beta Bionics has 353 employees.

What is the current trading status of Beta Bionics (BBNX)?

As of 01 Aug 2025, Beta Bionics (BBNX) is trading at a price of 16.79, with a previous close of 16.79. The stock has fluctuated within a day range of 16.57 to 17.50, while its 52-week range spans from 8.89 to 24.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.